More recently, Tirzepatide has gained attention for its potential role in longevity, offering promising benefits for long-term health and vitality
For weight management, tirzepatide (Zepbound) shows constipation rates of 17-26%, while semaglutide (Wegovy) reports approximately 24% at the 2.4 mg dose
As with all incretin-based therapies, questions have been raised regarding potential thyroid safety concerns, particularly the theoretical risk of medullary thyroid carcinoma (MTC)
Women of childbearing potential should be aware that Mounjaro can reduce the effectiveness of oral contraceptives
The seemingly paradoxical situation: in the approval trials, tirzepatide (5%) sits slightly above semaglutide/Wegovy (3%), while in the FAERS reporting system it is the other way round
Here is exactly what you need to know